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-catenin. GSK-3phosphorylates all three of these pro-
teins; however, phosphorylation of -catenin leads to
its degradation. Wnt stimulation inhibits the activity of
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GSK-3 within this complex, though mechanisms thatUniversity College London
may involve axin binding to the proteins Dishevelled (LiGower Street
et al., 2001) and LRP-5 (Mao et al., 2001). This allowsLondon, WC1E 6BT
unphosphorylated -catenin to accumulate in the cyto-United Kingdom
plasm and nucleus. By binding to TCF family transcrip-
tion factors, nuclear -catenin regulates transcription of
target genes such as c-myc and cyclin D1. MutationsThe structures of protein kinases, as resolved by X-ray
that perturb the function of the Axin-APC complex, suchcrystallography, have provided a set of useful paradigms
as truncation of APC or deletion of the GSK-3 sites ofto explain kinase regulation. The control of a handful of
-catenin, are present in 90% of colon cancers (Polakis,kinases, however, has proven more difficult to understand.
2000).Among these, glycogen synthase kinase-3 (GSK-3) has
Sequestration of GSK-3 within the axin complex doesbeen particularly perplexing, having a number of uncon-
not appear to be sufficient to prevent cross-talk withventional characteristics and acting within at least two
components of the insulin pathway. PKB phosphoryla-very different signal pathways. Recent results, including
tion of GSK-3 in the axin complex has been observedthe resolution of the GSK-3 protein structure, have now
after chronic and prolonged Wnt stimulation (Fukumotobegun to illuminate a sophisticated regulatory mecha-
et al., 2001), and alanine substitution of Ser-9 increasesnism that enables it to process different signals within
activity of GSK-3 within the Wnt pathway (Ding et al.,
the same cell.
2000). PKB phosphorylation, however, does not elicit
Insulin and Wnt Both Regulate GSK-3
the Wnt response (Ding et al., 2000). This makes sense,
GSK-3 was discovered and named as one of many pro-
as the effects of insulin and Wnt are different, even
tein kinases that phosphorylate and inactivate glycogen
in cells responsive to both signals. So how is GSK-3
synthase (Embi et al., 1980). Despite the specificity in-
regulated and how is cross-talk between the Wnt and
ferred by its name, GSK-3 is an important regulatory insulin pathways prevented?
kinase with a plethora of significant cellular targets, in- Structural Mechanisms for Kinase Regulation
cluding cytoskeletal proteins and transcription factors. The structure of GSK-3 suggests a mechanism for PKB
GSK-3 is of medical importance, being involved in meta- regulation of kinase activity; however, before consider-
bolic control, animal development, and oncogenesis. ing this structure, it is useful to think about the structural
GSK-3 is a downstream target of insulin stimulation and basis of the regulation of other kinases. The MAP kinase
regulates glycogen synthase, the protein translation ini- family is regulated by kinase activation through the spe-
tiation factor eIF2B, and the transcription factor C/EBP cific realignment of the residues that bind substrate and
(Cohen, 1999). Its regulation by insulin is important for catalyze phosphate transfer. This “activation segment”
the understanding of non-insulin-dependent diabetes is formed by phosphorylation at Thr-183 and Tyr-185,
mellitus, the most common metabolic disorder. GSK-3 and the switch between inactive and active conforma-
associates with presenilin and phosphorylates the mi- tions results in greater than a 1000-fold increase in ki-
crotubule-associated protein tau, implicating GSK-3 in nase activity (Canagarajah et al., 1997).
the progression of Alzheimer’s disease. GSK-3 is also In contrast, the cAMP-dependent protein kinase (PKA)
a central element of the Wnt signaling pathway and is is constitutively phosphorylated with its activation seg-
required for pattern formation during embryonic devel- ment held in an active conformation. PKA uses a
opment and regulation of cell proliferation (Dale, 1998). pseudo-substrate mechanism to regulate kinase activity
The GSK-3 protein family is highly conserved and has (Zheng et al., 1993). A pseudo-substrate is a short pro-
been found in animals, yeasts, Dictyostelids, and plants. tein sequence that conforms to the structure of the ki-
Two GSK-3 genes ( and ) have been cloned from nase substrate, but as it lacks an appropriately placed
vertebrates (Plyte et al., 1992). serine, threonine or tyrosine residue, it cannot be phos-
GSK-3 has strikingly different behavior to other pro- phorylated. As a consequence, a pseudo-substrate is
tein kinases. GSK-3 has a high basal activity within the a competitive inhibitor of kinase activity. The pseudo-
cell and both insulin and Wnt stimulation lead to a de- substrate of PKA is present on a separate protein, the
crease in kinase activity. In the case of insulin this is by regulatory subunit (R subunit), which binds the kinase
activation of protein kinase B (PKB), which phosphory- catalytic domain (C subunit). Kinase inhibition is re-
moved by dissociation of the R subunit due to bindinglates a serine residue in the N terminus, residue Ser-9 in
of cAMP. Pseudo-substrate mechanisms are also em-GSK3and Ser-21 in GSK3, and inhibits GSK-3 activity.
ployed by other kinases, for example protein kinase C,Wnt stimulation, on the other hand, acts on GSK-3 in
where the pseudo-substrate is present in the same pro-a multiprotein complex that also includes axin, adeno-
tein as the kinase domain.matous polyposis coli-associated protein (APC), and
Structure of GSK-3
Two groups, Dajani et al. (2001) and ter Haar et al. (2001),
report the resolution of the GSK-3 crystal structure.1 Correspondence: a.harwood@ucl.ac.uk
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Figure 1. A Pseudo-Substrate Mechanism
The “priming” phosphate (P4) of substrates
such as glycogen synthase interact with a
binding pocket in GSK-3 formed by Arg-96,
Arg-180, and Lys-205. Glycogen synthase is
phosphorylated on a serine (P0), which then
forms the priming phosphate for sequential
phosphorylations (dotted lines). A pseudo-
substrate within the N terminus can displace
the substrate from the binding pocket.
Based on protein sequence, GSK-3 is closely related to phosphorylation would not occur (Figure 1). Consistent
with this idea, peptides based on the sequence aroundCDK and MAP kinase families. Consistent with its pri-
mary sequence, GSK-3 conforms to the general struc- Ser-9 compete for substrate phosphorylation in a dose-
dependent manner, but only when Ser-9 is phosphory-ture of an activation segment protein kinase and much
of its structure resembles MAP kinase. It differs from lated (Dajani et al., 2001, Frame et al., 2001). In the
converse experiment, the Arg-96 mutant maintains ac-MAP kinase in the N-terminal portion of the kinase do-
main, which more closely resembles a tyrosine kinase, tivity after Ser-9 phosphorylation and hence is resistant
to inactivation by PKB (Frame et al., 2001). Finally thesuch as Src-kinase. This is interesting as GSK-3 has
been reported to have both serine/threonine and tyro- residues between Ser-9 and the kinase domain form a
loop long enough to reach the putative phospho-sub-sine phosphorylation activity (Wang et al., 1994). The
most surprising feature of the structure, however, is that strate interaction site (ter Haar et al., 2001). These results
strongly suggest that insulin-induced phosphorylationit forms an activation-segment in the absence of any
phosphorylation. can inhibit GSK-3 activity by generation of a pseudo-
substrate.The majority of GSK-3 substrates are formed by prior
phosphorylation from another kinase, an event known Specificity of Signaling Pathways
Based on their observations, Frame, Cohen, and Biondias “priming,” to give the structure S/T-X-X-X-S/T-P04;
where S/T corresponds to serine or threonine and X to (2001) further suggest a mechanism for maintaining sig-
nal pathway specificity. They observe that although in-any other residue. Priming phosphorylation occurs at
position P4 and GSK-3 transfers phosphate to position troduction of Arg-96 mutation causes a dramatic reduc-
tion in the ability of GSK-3 to utilize primed substrates,P0 (Figure 1). In the case of glycogen synthase GSK-3
phosphorylation site priming is due to casein kinase II. it has little effect on its phosphorylation of unprimed
substrates. Furthermore, short peptides of less thanOnce this site is phosphorylated by GSK-3, it then acts
as the priming phosphate to create an adjacent GSK-3 eight residues derived from the pseudo-substrate block
activity of wild-type protein against primed substrates,site. This then creates a third site, and subsequently
generates a fourth GSK-3 site. This unusual substrate but leave unprimed ones unaffected. This suggests that
GSK-3 may interact differently with the two forms ofpreference not only sets up the conditions for GSK-3 to
promote the incorporation of a large number of phos- substrate and complements results obtained using a
peptide known as FRATtide (Thomas et al., 1999). Thisphate moieties; it also forms the basis of its regulation
by PKB. Both structures are resolved without substrate, peptide is derived from the FRAT/GBP protein found in
vertebrates and is an inhibitor of GSK-3 activity in thebut are bound to either a HEPES molecule (Dajani et al.,
2001) or a phosphate ion (ter Haar et al., 2001). In both Wnt signaling pathway. In contrast to pseudo-substrate
peptides, FRATtide has little effect on GSK-3 phosphor-cases, these species interact with the positively charged
side chain head groups of Arg-96, Arg-180, and Lys- ylation of primed substrates, but inhibits unprimed sub-
strates (Figure 2). This is best illustrated with tau, a205. In MAP kinase the equivalent three residues interact
with phosphorylated Thr-183 residue, but in GSK-3 they protein substrate whose phosphorylation by GSK-3 is
virtually unaffected by FRATtide in its primed form butare positioned within the substrate binding cleft such
that they could bind the primed residue. In support of is strongly inhibited when not subject to prior phosphor-
ylation. These results again suggest that primed andthis, mutagenesis of residue Arg-96 greatly reduces
phosphorylation of primed GSK-3 substrates (Frame et unprimed may have different interactions with GSK-3.
Both axin and -catenin proteins can be phosphory-al., 2001). This structural feature may explain the prefer-
ence of GSK-3 for primed substrates and furthermore lated in vitro by GSK-3 without first carrying out a prim-
ing phosphorylation, and both are sensitive to FRATtidesubstrate binding may act to stabilize the active confor-
mation of the enzyme. inhibition (Thomas et al., 1999). This raises the possibility
that by binding to GSK-3, FRAT/GBP could selectivelyThe presence of a specific recognition site for primed
substrates suggests a pseudo-substrate mechanism for prevent phosphorylation of axin and -catenin. This has
also been seen by Farr et al. (2000) who again found thatGSK-3 regulation. Here PKB phosphorylation of Ser-9
could mimic the priming phosphorylation at P4, but as FRAT/GBP does not block phosphorylation of primed
substrates, but does block GSK-3-mediated -cateninthere is no corresponding serine or threonine at P0 GSK-3
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Figure 2. Differential Activity toward Primed
and Unprimed Substrates
In vitro phosphorylation of glycogen synthase
(a primed substrate) is inhibited by binding
of a pseudo-substrate (red), whereas interac-
tion with axin and -catenin (unprimed sub-
strates) is inhibited by binding FRATtide (blue).
degradation. Furthermore, Wnt stimulation via the pro- sine kinase, ZAK1, has been identified which activates
GSK-3 activity during Dictyostelium development. In ad-tein Dishevelled has been suggested to promote entry
of FRAT/GBP into the axin-GSK-3 complex (Li et al., dition, phosphorylation at position Tyr-216, the equiva-
lent of Tyr-185 in MAP kinase, has been observed in2001). FRAT/GBP may however have an alternative ef-
fect by interfering with GSK-3 binding to axin (Farr et GSK3 (Harwood, 2000). However, if phosphorylation
of this tyrosine is not required for generation of theal., 2000). These two putative roles could be combined
if FRAT/GBP remains bound to GSK-3 after dissociation activation segment, what role could it play? In the con-
formation seen in the GSK3 structure, the unphosphor-from the axin and perhaps prevents phosphorylation of axin
and -catenin, while at the same time allowing GSK-3 ylated Tyr-216 side chain is directed downward toward
the bottom of the substrate binding cleft, an orientationactivity toward glycogen synthase and regulation by
insulin. In this way, FRAT/GBP could biochemically re- which could impede, but not totally block, entry of a
phosphorylated residue at position P4 of the substratestrict the effect of Wnt stimulation but allow GSK-3 to
proceed with its other cellular functions. (Dajani et al., 2001; ter Haar et al., 2001). By comparison
to MAP kinase, phosphorylation could move Tyr-216The critical test for this restriction mechanism is to
demonstrate that it can occur within the cell, and it must away from the phosphate binding pocket. This suggests
that while not necessary for GSK-3 activation, phos-be pointed out that it has not been demonstrated that
either axin or -catenin is unprimed in vivo. Furthermore, phorylation could facilitate substrate binding and hence
kinase activity.GSK-3 has 400- to 1000-fold less activity against un-
primed peptide substrates than primed (Frame et al., The crystal structure of GSK3 shows it to be a tightly
opposed dimer. Dimers have been observed in crystals2001), a situation that is suggested to pertain for protein
substrates in vitro (Thomas et al., 1999). It is therefore of other protein kinases, including the MAP kinase ERK2.
Here, dimerization leads to accumulation of ERK2 in theunclear whether unprimed proteins substrates are true
cellular GSK-3 targets, although bringing GSK-3 and its nucleus (Cobb and Goldsmith, 2000). The GSK-3 dimer
is in a head-to-tail orientation with the surface of onesubstrates together in a complex could promote phos-
phorylation of what may be a biochemically unfavorable monomer interacting with the predicted substrate bind-
ing site of the other. This could block entry of substratereaction. Examination of the in vivo behavior of the Arg-
96 mutant should establish the physiological relevance into the dimer. Interestingly, the side chain of Tyr-216
participates in the dimer interface and phosphorylationof GSK-3 activity against unprimed substrates. A final
problem is that FRAT/GBP has not been found outside of Tyr-216 would be predicted to interfere with dimeriza-
tion by causing rotation to the “up” conformation (Dajanithe vertebrates, this means that either FRAT/GBP inhibi-
tion is not the only mechanism to regulate GSK-3 activity et al., 2001). This offers the potential for a novel mecha-
nism of GSK-3 regulation and a possible additional rolein the axin complex, or other FRAT-like proteins await
discovery. In principle, however, any mechanism that for tyrosine phosphorylation. None of these predictions
have been verified either in vitro or in vivo.displaces GSK-3 or an unprimed -catenin protein from
the axin complex could prevent its phosphorylation. Concluding Remarks
The structure, biochemistry and effect of mutagenesisTyrosine Phosphorylation and Dimerization
The structure of GSK-3 also sheds light on other mecha- suggest a more complex regulation of GSK-3 than pre-
viously imagined. This protein kinase is able to processnisms of GSK-3 regulation. In addition to being under
negative regulation, GSK-3 can be activated and a tyro- at least two different stimuli and deliver distinct out-
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comes. This in part may be due to compartmentalization
of GSK-3 action within the cell, but what these recent
results suggest is that specificity could also be achieved
by intrinsic properties of GSK-3. These could allow a
common pool of GSK-3 to participate in multiple path-
ways, but limit inappropriate cross-talk. These results
may also lead to the design of function-specific drugs
that disrupt some actions of GSK-3, but leave others
intact. To date much of our knowledge of GSK-3 activity
is based on in vitro studies. With the GSK-3 structure,
we are now in the position to design mutant proteins
that lack some but not all of the kinase properties and
test our knowledge gained in vitro in the context of
the cell.
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